The Biochip of Gene Target Group Recognized by the Ministry of Economic Affairs' TIIP Program, Drivi

Taiwan’s Semiconductor Chip Industry Leads the World with Over NT$4 Trillion Output Annually, While Gene Target Group’s Genetic Biochip Poised to Become the Nation’s Second “Protective Mountain”

Taiwan’s semiconductor industry, backed by strong national support and sustained industrial investment, has achieved an impressive annual output exceeding NT$4 trillion, earning global recognition as the nation’s “Protective Mountain.” Following this success, Taiwan is on the cusp of a second “Protective Mountain” rising from the health technology sector—the Gene Target Group’s Genetic Biochip, which promises precise genetic decoding, disease prevention, virus detection, and diagnostic applications. This innovation is set to elevate Taiwan as a leader in the global precision health industry.

Dr. Yifang Chen, founder of Gene Target Group and chairperson of the International Precision Health Development Association, notes that the COVID-19 pandemic has accelerated leaps in the biomedical industry worldwide. The PCR nucleic acid testing equipment market alone is projected to exceed US$30 billion annually. According to forecasts by Taiwan’s Bioindustry Development Association, the global precision health market is expected to surpass NT$4.5 trillion by 2025. The U.S. Technology Policy Research and Information Center also reports that the booming precision health industry and post-pandemic demand for genetic technology will drive gene chip supply and applications to an estimated annual output exceeding NT$7 trillion.

With Taiwan’s rich experience and outstanding achievements in biotechnology, the success of gene chip technology could replicate the semiconductor industry’s miracle, creating Taiwan’s second “Protective Mountain.”